[Important antitumoral immunity and a favorable clinical outcome in two patients receiving an autologous vaccine].
The anti-tumor immune response was studied on two patients. The first patient is still alive, fifteen years after the diagnosis of a cutaneous melanoma and this, despite unique recurrent metastases. She receives regularly an autologous vaccine. The second patient is alive ten years after the diagnosis of a lung cancer, and benefit also of an autologous vaccine. The immune response of these two patients is mostly directed against a strictly tumor-specific antigen. These important responses are easily detectable in their blood using a new tool: soluble HLA-peptides complexes. Each time, there is an oligoclonal response where one clone is largely dominant. Moreover, there are some elements suggesting that these responses may have influenced the favorable clinical evolution of these two patients.
Baurain
J Fr
JF
Unité d'Oncologie médicale, Cliniques universitaires Saint-Luc, U.C.L.
D000328:Adult; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000628:therapy; D008875:Middle Aged; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome
D019496:Cancer Vaccines